Novartis entered into agreement to buy Endocyte, the company with the world license for LU 177 PSMA 617 .

[tango65]

markets.businessinsider.com...

globenewswire.com/news-rele...

[Schwah]

That’s what I was afraid of. I suppose the good news is that those in the know must believe in the efficacy of the product and it’s ability to help PC patients.

Schwah.

[GP24]

The therapy was developed in Heidelberg financed with taxpayer's money. Now the taxpayers will have to pay a fortune to receive this treatment if they get prostate cancer.

[Fairwind]

This is why new cancer treatments are SO expensive...The first thing Novatris will have to do is recover their $2.1 Billion "investment"..The tiny research company, Endocyte, just made more money than they ever could developing the treatment and marketing it..This is a glaring example why "For Profit" medicine needs to be rained in. Lifesaving drugs and treatments that have been developed at taxpayer expense should never be granted exclusive patents...